Analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to post earnings per share of ($0.19) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Abeona Therapeutics’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.20). Abeona Therapeutics reported earnings of ($0.16) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 18.8%. The firm is scheduled to issue its next earnings report on Wednesday, May 5th.
According to Zacks, analysts expect that Abeona Therapeutics will report full year earnings of ($0.74) per share for the current year, with EPS estimates ranging from ($0.79) to ($0.68). For the next year, analysts anticipate that the company will post earnings of ($0.70) per share, with EPS estimates ranging from ($0.82) to ($0.57). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Tuesday, March 23rd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.07). The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $5.55 million.
Several equities analysts recently issued reports on the company. Zacks Investment Research cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, February 19th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, April 14th. Finally, SVB Leerink reissued a “buy” rating on shares of Abeona Therapeutics in a research note on Monday, March 29th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $4.71.
In other news, Director Sco Capital Partners Llc sold 240,000 shares of Abeona Therapeutics stock in a transaction on Monday, February 8th. The stock was sold at an average price of $3.01, for a total transaction of $722,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Edward Carr sold 35,000 shares of Abeona Therapeutics stock in a transaction on Monday, April 5th. The stock was sold at an average price of $1.80, for a total value of $63,000.00. Following the transaction, the chief accounting officer now directly owns 226,291 shares of the company’s stock, valued at approximately $407,323.80. The disclosure for this sale can be found here. In the last three months, insiders sold 742,199 shares of company stock valued at $1,838,485. 19.10% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in shares of Abeona Therapeutics by 20.5% during the 4th quarter. Rhumbline Advisers now owns 89,874 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 15,299 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Abeona Therapeutics by 26.9% during the 4th quarter. Wells Fargo & Company MN now owns 80,942 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 17,168 shares during the last quarter. Credit Suisse AG acquired a new position in shares of Abeona Therapeutics during the 4th quarter worth $27,000. WealthTrust Axiom LLC acquired a new position in shares of Abeona Therapeutics during the 1st quarter worth $35,000. Finally, Assenagon Asset Management S.A. raised its stake in shares of Abeona Therapeutics by 15.2% during the 1st quarter. Assenagon Asset Management S.A. now owns 145,528 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 19,184 shares during the last quarter. 36.47% of the stock is owned by institutional investors and hedge funds.
ABEO stock traded up $0.09 during trading on Friday, hitting $1.77. The company had a trading volume of 2,020,453 shares, compared to its average volume of 3,498,647. The firm has a market cap of $175.30 million, a PE ratio of -1.70 and a beta of 1.69. Abeona Therapeutics has a 1-year low of $0.99 and a 1-year high of $3.79. The firm has a 50-day moving average price of $1.82 and a 200-day moving average price of $1.79.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Recommended Story: How to Invest in a Bull Market
Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
